Sign in →

Test Code LAB3498 Thrombosis Risk DNA Panel

Important Note

The panel includes simultaneous testing for the factor V Leiden mutation in the F5 gene & the prothrombin variant c.20210G>A in the F2 gene.  This test is indicated for individuals with a history of venous thromboembolism (VTE) as part of thrombophilia work up.  

Clinical System Name

Thrombosis DNA Screen

Sample Requirements

Specimen: Whole Blood

Container(s): Lavender/EDTA or Yellow/ACD A or B
Preferred Vol: 3.0 mL

Minimum Vol: 2.0 mL

 

Specimen: DNA

Container(s): Sterile plastic tube

Preferred Vol: 20-30 ul of 100ng/ul concentration

 

Alternative Specimen (e.g. salvia or buccal): Alternate Specimen Collection Kits for Genetic Testing

 

Processing Instructions

Reject due to: Heparin

Spin: No

Aliquot: No

Temp: Refrigerate

Storage location: CPA refrigerator sendouts rack

Stability

Specimen Type Temperature Time
Whole blood Room temp 3 d
  Refrigerated 7 d
  Frozen Unacceptable
Extracted DNA Room temp 3-4 d
  Refrigerated 1 y
  Frozen Indefinitely

 

Availability

STAT Performed TAT
Contact lab Weekly 1 w

 

Performing Laboratory

University of Washington

Dept of Laboratory Medicine

UW Genetics Lab

1959 NE Pacific St, NW220
Seattle, WA 98195
 

Phone Number: (206) 520-4600

Department

Department: Send Outs/Genetic

Phone Number: (206) 987-2563

Reference Range

Interpretive report will be provided

Methodology

Method: PCR

Special Instructions

UWMC

Requisition

 

Clinical Utility

Factor V Leiden Thrombophilia Gene Review 

Prothrombin Related Thrombophilia GeneReview

 

The factor V Leiden mutation is the most common cause of activated protein C (APC) resistance, and most common genetic risk factor for thrombosis. Approximately 3-8% of the population is heterozygous, and have an estimated 5-10 fold increased risk of thrombosis. Homozygotes have a 50-100 fold increased risk.

The common prothrombin c.20210G>A variant is associated with elevated prothrombin levels, which promotes development of fibrin clots. 2-4 % of the population is heterozygous for PTV 20210. Heterozygotes have an estimated 3-11 fold increased risk of thrombosis.

Send Out Instructions

 

Reference Test Name: Thrombophilia DNA Screen
Reference Test Number: TPDS
Instructions: Send out M - F with the UW courier.

Exclude from UM database

Related Tests